Skip to main content

Market Research Outlook

MRO Tracker · Pharma

When each protected medicine opens to Indian generics and biosimilars, and which Indian companies are already lined up. We list a molecule only when its Indian expiry date is confirmed in a court record or official filing.

7patents with confirmed Indian dates
2opening before the end of 2026
12 Decnext opening: ruxolitinib
6Indian pembrolizumab developers in CDSCO trials

Download this tracker as Excel

MRO View: In India the patent date is only the start. Firms that were restrained before expiry usually have product ready and launch on day one, and a strong validity challenge can open a market years early, as risdiplam showed.

Cancer · Incyte; sold in India as Jakavi by Novartis since 2013

Ruxolitinib

Status
Opens 12 Dec 2026
Indian patent
IN 269841, in force until 12 December 2026
Indian firms waiting
Shilpa Medicare (restrained January 2026), Aurore Life Sciences (restrained July 2026) and Melody Healthcare (restrained 24 September 2026) were all stopped from selling before expiry
Price control
Not in NLEM 2022
Approved uses
Myelofibrosis, polycythaemia vera, graft versus host disease
MRO View: The next major molecule to open in India. Three firms already tried to move early, which tells you the queue is real. Expect several launches in the first weeks after 12 December.

Cancer · Pharmacyclics (AbbVie); sold in India as Imbruvica by Johnson & Johnson

Ibrutinib

Status
Opens end 2026
Indian patent
IN 262968. Court orders describe it as valid until 2026; the exact day is not stated in the orders we reviewed
Indian firms waiting
Natco, Hetero, BDR Pharma, Shilpa Medicare, Alkem and Laurus Labs restrained in December 2023; Emcure undertook in May 2025 not to sell until expiry
Price control
Not in NLEM 2022
Approved uses
Chronic lymphocytic leukaemia and other B cell blood cancers
MRO View: Seven Indian firms already have product or API ready, because they sold it before the 2023 restraint. This should be one of the fastest generic launches of the decade.

Cancer · MSD (Keytruda)

Pembrolizumab

Status
Opens June 2028
Indian patent
Runs to June 2028
Indian firms preparing
CDSCO expert panels cleared or reviewed biosimilar trials by Enzene, Hetero, Intas and Sun Pharma (2025 to 2026), Shilpa Biologicals (protocol approved with changes, October 2026) and Zydus (ZRC 3323, changes asked, October 2026)
Price control
Not in NLEM 2022
Approved uses
Many cancers including lung, melanoma, head and neck
MRO View: The biggest biologic opening of the decade. At least six Indian developers are in the CDSCO trial queue, so launch timing will be set by who finishes trials first, not by the patent.

Cancer · Novartis (Tafinlar)

Dabrafenib

Status
Opens 4 May 2029
Indian patent
In force until 4 May 2029
Indian firms waiting
Zydus is bound by an August 2026 Delhi High Court decree not to launch before expiry; development work under the Bolar exemption is allowed
Price control
Not in NLEM 2022
Approved uses
BRAF V600 mutated melanoma and lung cancer, usually with trametinib
MRO View: A niche but high value oncology launch. Pairing with a trametinib supply plan will matter.

Supportive care · Helsinn (Akynzeo)

Netupitant + palonosetron

Status
Opens 18 Nov 2030
Indian patent
Composition and method patent granted 23 March 2023, valid until 18 November 2030
Indian firms waiting
Intas restrained in November 2026 after launching NO CINV; an earlier challenge by Zydus was dismissed
Price control
Not in NLEM 2022
Approved uses
Preventing nausea and vomiting from chemotherapy
MRO View: A later formulation patent is holding the market, not the original molecule. Entrants need a design around or a revocation case, not just a calendar date.

Cancer · AstraZeneca (Tagrisso)

Osimertinib

Status
Opens 2032
Indian patent
IN 297581, in force to 2032
Indian firms waiting
Post grant oppositions by Natco and Sunshine Organics failed; Westcoast Pharmaceutical Works is under a permanent injunction
Price control
Not in NLEM 2022
Approved uses
EGFR mutated non small cell lung cancer
MRO View: Patents are holding in court. Planning should assume no generic before 2032.

Rare disease · Roche (Evrysdi)

Risdiplam

Status
Contested; patent to 11 May 2035
Indian patent
IN 334397, term to 11 May 2035
Indian firms selling
Natco, after the Delhi High Court refused Roche an interim injunction in March 2025 and Roche lost its appeals
Price control
Not in NLEM 2022
Approved uses
Spinal muscular atrophy
MRO View: Proof that a patent date is not the same as market exclusivity in India. A credible validity challenge opened this market nine years early.

On watch: patent position contested, no confirmed expiry date

  • Ribociclib (Novartis, Kisqali): a second Indian patent was granted in 2026 after a 15 year delay. Natco has asked the Delhi High Court to revoke it. In September 2026 the Kerala High Court held that the government may use Section 100 of the Patents Act to supply patented medicines.
  • Vericiguat (Bayer): the Delhi High Court granted an interim injunction on Indian Patent 316570 in October 2026.

Already opened: 2019 to 2026

Molecules whose main Indian patent has expired or been revoked, with what happened next. Makers, prices and price control for these and 43 other molecules are in the Drug Market Entry Tracker.

MoleculeOriginator (brand)Opened onWhat happened
NivolumabBristol Myers Squibb (Opdivo)2 May 2026Indian patent expired. The Supreme Court had dismissed a BMS petition on 11 February 2026.
SemaglutideNovo Nordisk (Ozempic, Rybelsus, Wegovy)20 March 2026Product patent IN 262697 expired. Indian makers launched the next day.
Sacubitril + valsartanNovartis (Vymada)12 September 2025Patent IN 414518 revoked. Natco, Torrent, MSN and Eris were cleared to sell.
LinagliptinBoehringer Ingelheim (Trajenta)August 2023Patent expired. About 63 brands followed.
Dapagliflozin (second patent)AstraZeneca (Forxiga)15 May 2023Species patent IN 235625 expired. The Delhi High Court had refused an interim injunction.
ApixabanBristol Myers Squibb and Pfizer (Eliquis)17 September 2022Patent IN 247381 expired after suits against Cipla, Micro Labs, BDR and others.
DapagliflozinAstraZeneca (Forxiga)2 October 2020Patent IN 205147 expired. Zydus launched Dapaglyn on 4 October 2020.
VildagliptinNovartis (Galvus)9 December 2019Patent IN 212815 expired. Zydus launched Vinglyn at Rs 4.95, one sixth of the original price.

Dates are taken from Delhi High Court orders and Patent Office records. A later patent on a form or formulation can still block launches after the main date. This is not legal advice.

Get the monthly India tracker updateNew state data and new plant announcements in one short email, once a month.

One email a month. Reply to any email to unsubscribe. Privacy policy

Frequently asked questions

Which drug patent expires next in India?

Ruxolitinib, on 12 December 2026. Ibrutinib follows at the end of 2026.

When does pembrolizumab go off patent in India?

The Indian patent runs to June 2028. At least six Indian companies are in CDSCO biosimilar trials.

Can a generic launch before the patent date in India?

Only if the patent is revoked or a court refuses an injunction, as happened with risdiplam. Otherwise firms that launch early are restrained, as with ruxolitinib and ibrutinib.

Download this tracker as Excel

Every row on this page in one spreadsheet, ready to filter and share with your team. Free for internal use.

We use your details only to share related MRO research. See our privacy policy.

Go deeper

Planning a launch on one of these dates?

We map the patent, the competing makers and the price fall to expect for your molecule.